ClinicalTrials.gg
CompletedNCT05357716PRE-ALERTUpdated Sep 15, 2026

Preliminary Research Evaluation for Ambulatory Leadless Electrocardiogram Recorder Trial

An observational study in Atrial Fibrillation, Tachycardia, Supraventricular and Bradyarrhythmia, sponsored by HelpWear Inc.. Completed at 1 site in Canada. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by HelpWear Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 318 studies in Atrial Fibrillation with a site in Canada — 50 open to participants now, 73 under way, 8 of them phase 3. Atrial Fibrillation · Canada.

Enrollment
56th of 57
7 · median 297
Started
2020
with 17 others
Observational
57 of 318
10 open now
Registered
260th of 318
by date

Among the 318 studies in Atrial Fibrillation with a site in Canada, this one is the 56th largest by enrollment of the 57 observational ones that give a count, is one of 18 that started in 2020, is one of 57 observational ones, and was the 260th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

50 of the 318 studies in Atrial Fibrillation with a site in Canada are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 318 studies in Atrial Fibrillation with a site in Canada, or all of them as a file.
02

Study summary

The clinical study is intended to implement and test the collection and analysis of paired ECG data from the HeartWatch and two comparator devices, an Event Recorder and Holter. The HeartWatch is indicated for extended diagnostic evaluation of patients with transient symptoms of possible cardiac origin such as syncope and palpitations, as well as patients at risk for arrhythmias, but without significant symptoms. While the use of the device itself can be managed by both healthcare professionals and patients, interpretation of the collected data for diagnosis is restricted to healthcare professionals, as the data must be loaded and analyzed separately after recording. Patients indicated for extended ambulatory ECG testing will be approached for participation. Subjects will wear the HeartWatch and an Event Recorder for up to 72 hours or the HeartWatch and Holter monitor for up to 48 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Event recorder subjects will collect user-triggered and auto-triggered data, while Holter subjects will record diary information on their activities and any relevant symptoms. Adverse events and user preference for one device versus the other being used in that arm will also be collected from all subjects. Paired ECG data from the HeartWatch and comparator devices is expected to be similar in terms of the events documented and the proportion of data that is clinically interpretable.

03

Conditions studied

  • Atrial Fibrillation
  • Tachycardia, Supraventricular
  • Bradyarrhythmia
  • Ventricular Arrythmia
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients referred to participating clinics for extended ambulatory ECG testing. Subjects referred for extended ambulatory ECG testing will be recruited from the Toronto Heart Centre. Referring physicians will be asked to indicate if longer-term (i.e., Event Recorder) or shorter-term monitoring (i.e., Holter monitor) is desired for a given patient.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 22 years of age at time of consent
  • Clinically-indicated for an ambulatory Event Recorder or Holter monitor
  • Able to follow the protocol
  • Provision of written-

Exclusion criteria

Exclusion Criteria:

  • Known allergy to any component of the Event Recorder
  • Known allergy to any component of the Holter monitor
  • Known allergy to any component of the HeartWatch
  • Dextrocardia
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7 participants (actual)
Patient registry
No

Groups and cohorts

  • Arm A

    Up to 40 patients will be enrolled in Arm A. Subjects will wear the HeartWatch and an Event Recorder for up to 72 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Event recorder subjects will collect user-triggered and auto-triggered data.

    Device: HeartWatch · Device: Event Recorder

  • Arm B

    Up to 10 patients will be enrolled in Arm B.Subjects will wear the HeartWatch and Holter monitor for up to 48 hours. Subjects will be asked to document their activities (standing, sitting, walking, exercise, or laying down). Holter subjects will record diary information on their activities and any relevant symptoms.

    Device: HeartWatch · Device: Holter Monitor

Interventions

  • DeviceHeartWatch

    The HeartWatch arm band provides continuous, high-quality single lead electrocardiograph (ECG) data in a variety of environments. The ECG data is transmitted via Bluetooth and stored on the user's smartphone. It is then uploaded to the cloud for subsequent analysis using either a commercial ECG software package or a customized software package from HelpWear.

  • DeviceEvent Recorder

    A standard 1 or 2-lead Sirona Event Recorder will be used to collect high-resolution data. Subjects will be asked to wear the clinical monitor for at least 48 hours and no longer than 84 hours. ECG signals will be continuously collected as long as the skin patches are attached to the skin and the recorder is properly connected to the wires.

  • DeviceHolter Monitor

    A standard 5-lead SEER Holter will be used to collect 3-channels of high-resolution data. Subjects will be asked to wear the clinical, conventional monitor for at least 36 hours and no longer than 60 hours. During this time ECG signals will be continuously collected.

06

What researchers measure

Primary outcomes

  1. Pairing HeartWatch and Event Recorder

    Can paired user-triggered (tagged) and auto-triggered ECG data from the HeartWatch and Event Recorder be successfully collected?

    Time frame: Up to 6 months, with 3 months of analysis time (9 months total)

  2. Pairing HeartWatch and Holter

    Can paired continuous ECG data from the HeartWatch and Holter monitor be successfully collected?

    Time frame: Up to 6 months, with 3 months of analysis time (9 months total)

Secondary outcomes

  1. Body Position and Activity

    Does body position and activity affect the quality of the HeartWatch, Event Recorder, and Holter data?

    Time frame: Up to 6 months, with 3 months of analysis time (9 months total)

Other outcomes

  1. Adverse Events

    Incidence of adverse events among the HeartWatch and comparator devices and the types of adverse events

    Time frame: Up to 6 months, with 3 months of analysis time (9 months total)

  2. User Preferences

    User preferences of subjects with the HeartWatch versus the comparator devices

    Time frame: Up to 6 months, with 3 months of analysis time (9 months total)

07

Study locations

1 site
  • HelpWear Inc
    Toronto, Ontario M5B1T8, Canada
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Oct 2023, 34 months.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's 34 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
May 3, 2022
StartActual
Nov 15, 2020
Primary completionActual
Oct 2, 2023
CompletionActual
Oct 2, 2023
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05357716
Lead sponsor
HelpWear Inc.
Responsible party
Sponsor
First posted
May 3, 2022
Start date
Nov 15, 2020
Primary completion
Oct 2, 2023
Completion
Oct 2, 2023
Last update
Sep 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion